SCP
CLDX icon

Sender Company & Partners’s Celldex Therapeutics CLDX Stock Holding History

Sender Company & Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$425K Buy
+13,400
New +$365K 0.26% 38
2025
Q3 		– Sell
-13,000
Closed -$265K – 485
2025
Q2 		$265K Buy
+13,000
New +$253K 0.07% 217

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Sender Company & Partners's CLDX Position: Q3 2025 in Review

Sender Company & Partners sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 15,593 shares — an estimated $317K sold.

Sender Company & Partners first reported a position in CLDX in Q2 2025 and held it in 1 quarter. The position peaked at $317K in Q2 2025. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • Sender Company & Partners reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sender Company & Partners sold 15,593 Celldex Therapeutics shares in Q3 2025, an estimated $317K.
  • Sender Company & Partners first reported a position in Celldex Therapeutics in Q2 2025 and held it in 1 quarter.
  • Sender Company & Partners's Celldex Therapeutics position peaked at $317K in Q2 2025.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Sender Company & Partners's 13F filing for Q3 2025, filed 17 Nov 2025.